Eurofins Scientific SE (EPA:ERF)
France · Delayed Price · Currency is EUR 80.90
+1.90 (2.41%)
Oct 21, 2026, 5:35 PM CEST
Eurofins Scientific SE Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 7,386 | 7,296 | 6,951 | 6,515 | 6,712 | 6,718 |
Revenue Growth | 1.23% | 4.96% | 6.70% | -2.94% | -0.08% | 23.51% |
Gross Profit Gross Profit Growth | 1,708 | 1,641 | 1,552 | 1,364 | 1,513 | 1,902 |
Operating Income Operating Income Growth | 1,040 | 963.7 | 897.8 | 717 | 908.7 | 1,358 |
Net Income Net Income Growth | 469.9 | 416.1 | 356.3 | 256.5 | 580.9 | 748.5 |
Earnings Per Share EPS Growth | 2.56 | 2.23 | 1.83 | 1.30 | 2.92 | 3.73 |
EPS Growth | 14.71% | 21.86% | 40.77% | -55.48% | -21.72% | 44.57% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Life Life Growth | 3,117 | 3,043 | 2,869 | 2,607 |
BioPharma BioPharma Growth | 2,059 | 2,062 | 2,010 | 1,970 |
Diagnostic Services & Products Diagnostic Services & Products Growth | 1,510 | 1,496 | 1,370 | 1,276 |
Consumer & Technology Products Testing Consumer & Technology Products Testing Growth | 700 | 695 | 702 | 661 |
Revenue (Total) Revenue (Total) Growth | 7,385 | 7,296 | 6,951 | 6,515 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 617.8 | 794.2 | 615.9 | 1,226 | 492.2 | 515.8 |
Total Debt Total Debt Growth | 4,472 | 4,432 | 3,610 | 3,927 | 3,326 | 2,754 |
Net Cash (Debt) Net Cash Growth | -3,854 | -3,638 | -2,994 | -2,701 | -2,833 | -2,238 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -20.93 | -19.51 | -15.40 | -13.65 | -14.24 | -11.16 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,487 | 1,399 | 1,319 | 1,018 | 1,136 | 1,511 |
Capital Expenditures CapEx Growth | -729.6 | -759.9 | -453.6 | -478.1 | -576.1 | -444.4 |
Free Cash Flow Free Cash Flow Growth | 757.2 | 639 | 865.3 | 539.8 | 560.2 | 1,067 |
Free Cash Flow Growth | 18.50% | -26.15% | 60.30% | -3.64% | -47.50% | 16.91% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 23.13% | 22.49% | 22.33% | 20.93% | 22.54% | 28.31% |
Operating Margin | 14.08% | 13.21% | 12.92% | 11.01% | 13.54% | 20.22% |
Pretax Margin | 9.84% | 8.97% | 7.98% | 6.50% | 11.62% | 15.73% |
Profit Margin | 6.36% | 5.70% | 5.13% | 3.94% | 8.65% | 11.14% |
FCF Margin | 10.25% | 8.76% | 12.45% | 8.29% | 8.35% | 15.88% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.720 | 0.720 | 0.600 | 0.500 | 1.000 | 1.000 |
Dividend Per Share Growth | 20.00% | 20.00% | 20.00% | -50.00% | 0% | 47.06% |
Dividend Yield | 0.89% | 1.15% | 1.21% | 0.85% | 1.49% | 0.92% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.88 | 26.52 | 26.03 | 44.19 | 22.21 | 27.91 |
Forward PE | 18.06 | 15.40 | 14.20 | 19.87 | 17.67 | 28.49 |
P/FCF Ratio | 18.11 | 17.27 | 10.72 | 21.00 | 23.03 | 19.58 |
PS Ratio | 1.86 | 1.51 | 1.33 | 1.74 | 1.92 | 3.11 |